Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06382688 · ClinicalTrials.gov registry record · NA
IV Administration of ChromaDex's Niagen® as Compared to NAD+
A NA study of Healthy Aging, sponsored by Nutraceuticals Research Institute.
- Active
- Registry status
- NA
- Development phase
- 53
- Enrollment target
- 1
- Study location
NCT06382688: Active NA study of Healthy Aging, sponsored by Nutraceuticals Research Institute.
NCT06382688 is a NA study of Healthy Aging that is active but no longer recruiting, run by Nutraceuticals Research Institute. The registered enrollment target is 53 participants, below the 120-participant average among 40 other Healthy Aging trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06382688, a NA study of Healthy Aging, is active but no longer recruiting, sponsored by Nutraceuticals Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 53 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a 2-part study evaluating the effects of IV administration of NR on healthy adult populations. Study 1 involved all four arms with 37 people. The second study only included the active NR and NAD+ arms to further evaluate tolerability and comfort of the IV.
Conditions Studied
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT NAD+ (nicotinamide adenine dinucleotide) IV
- DIETARY_SUPPLEMENT Niagen® (nicotinamide riboside) IV
- DIETARY_SUPPLEMENT Niagen® (nicotinamide riboside) oral
Study Locations (1)
Tennessee
- Nutraceuticals Research Institute - Franklin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2023-11-13 |
| Est. Completion | 2024-08-31 |
| Phase | NA |
What the registry record for NCT06382688 still lists
NCT06382688 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 120-participant average among 40 other Healthy Aging trials with a reported enrollment target (56% lower).
The record links to 1 condition, with Healthy Aging appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT06382688 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT06382688 about?
NCT06382688 is a clinical study titled "IV Administration of ChromaDex's Niagen® as Compared to NAD+". This is a 2-part study evaluating the effects of IV administration of NR on healthy adult populations. Study 1 involved all four arms with 37 people. The second study only included the active NR and NAD+ arms to further evaluate tolerability and comfort of the IV.
What is the current status of trial NCT06382688?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 53 participants. The study started on 2023-11-13. Estimated completion is 2024-08-31.
What conditions does trial NCT06382688 study?
This clinical trial studies the following conditions: Healthy Aging.
What interventions are being tested in trial NCT06382688?
The interventions under investigation include: Placebo (OTHER), NAD+ (nicotinamide adenine dinucleotide) IV (DIETARY_SUPPLEMENT), Niagen® (nicotinamide riboside) IV (DIETARY_SUPPLEMENT), Niagen® (nicotinamide riboside) oral (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06382688?
This trial is sponsored by Nutraceuticals Research Institute, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06382688 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Aging
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06382688's enrollment target sits among peer trials
53 30th of 40 higher than 11 of 40 other Healthy Aging trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Aging trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Executive Control in Cognitively Healthy Older Adults: the MUltitasking STrategy (MUST) Study
RECRUITING · NA
-
The Mitopure Challenge to Detect Levels of Urolithin A in Dried Blood Spots
RECRUITING · NA
-
Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+
RECRUITING · NA
-
Disease Modifying Potential of 5mg of Melatonin on Cognition and Brain Health in Aging
RECRUITING · NA
-
iVS-1 Probiotic Intervention Targeting Biological Aging in Midlife Adults
RECRUITING · NA
-
Reactive Balance Training for Fall Prevention
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI